

RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

Approved for use through 10/31/02 by OMB 031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/082,443
	Filing Date	February 22, 2002
	First Named Inventor	Mark R. ALVIS et al.
	Group Art Unit	1614
	Examiner Name	To Be Assigned
Total Number Of Pages In This Submission	14 + 79 References	Attorney Docket No. 437252001200

ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	<ul style="list-style-type: none">• Form PTO-1449 + copy - 10 Pages• Seventy-Nine (79) References• Return Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement - 3 Pages	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT

Firm or Individual Name	Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018
Signature	Kimberly A. Bolin, Registration No. 44,546
Date	May 9, 2002

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 9, 2002.

Barbara M. Weatherly

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.



RECEIVED

MAY 16 2002

TECH CENTER 1600/2900

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on May 9, 2002.

Barbara M. Weatherly

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mark R. ALVIS et al:

Serial No.: 10/082,443

Filing Date: February 22, 2002

For: METHODS AND COMPOSITIONS FOR
IMPROVED ARTICULAR SURGERY
USING COLLAGEN

Examiner: To Be Assigned

Group Art Unit: 1614

INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly, no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.


Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, Applicants petition for any required relief including extensions of time and authorize the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1952 referencing 437252001200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.



Dated: May 9, 2002

Respectfully submitted,

By: 
Kimberly A. Bolin
Registration No. 44, 546


Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5740
Facsimile: (650) 494-0792

Form PTO-1449	Docket Number 437252001200	Application Number 10/082,443
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Applicant Mark R. ALVIS et al.	
	Filing Date: February 22, 2002	Group Art Unit: 161
	Mailing Date: May 9, 2002	



U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date if Appropriate
	1.	04/06/1976	3,949,073	Daniels et al.			
	2.	06/29/1976	3,966,908	Balassa			
	3.	02/20/1979	4,140,537	Luck et al.			
	4.	11/11/1980	4,233,360	Luck et al.			
	5.	02/10/1981	4,250,139	Luck et al.			
	6.	07/05/1983	4,391,749	Engvall et al.			
	7.	01/03/1984	4,424,208	Wallace et al.			
	8.	09/25/1984	4,473,551	Schinitsky			
	9.	04/15/1986	4,582,640	Smestad et al.			
	10.	10/27/1987	4,703,108	Silver et al.			
	11.	11/03/1987	4,704,273	McMichael			
	12.	07/26/1988	4,760,131	Sundsmo et al.			
	13.	08/16/1988	4,764,377	Goodson			
	14.	02/14/1989	4,804,745	Koepff et al.			
	15.	03/06/1990	4,906,670	Higashi et al.			
	16.	03/26/1991	5,002,071	Harrell			
	17.	07/30/1991	5,036,056	Kludas			
	18.	04/01/1997	5,616,689	Shenoy et al.			
	19.	06/17/1997	5,639,796	Lee			
	20.	07/04/2000	6,083,918	Klaus			
	21.	07/11/2000	6,087,355	Cho et al.			
	22.	12/26/2000	6,165,983	Klaus			
	23.	11/13/2001	6,316,015 B1	Rondelez et al.			
	24.	11/13/2001	6,316,033 B1	Lin			
	25.	11/27/2001	6,322,592 B2	Lucas et al.			



EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

MAY 20 2002

PTO/SB/08 (2-92)
Sheet 2 of 5

Form PTO-1449	TECH CENTER 1600/2900	Book Number 437252001200	Application Number 10/082,443
INFORMATION DISCLOSURE CITATION IN AN APPLICATION 3 2002 (Use several sheets if necessary)		Applicant Mark R. ALVIS et al.	
		Filing Date: February 22, 2002	Group Art Unit: 1614
		Mailing Date: May 9, 2002	

12/06/2001	Application No. 20010049366	Singh et al.				
01/10/2002	Application No. 20020004499	Rudnic et al.				

RECEIVED
MAY 16 2002
TECH CENTER 1600/2900

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	28.	10/25/1989	EP 338813	EPO				
	29.	11/1981	SU 880426	Russia			X (Abstract)	

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	30.	Altman, R. D. (1992) "Laboratory Findings in Osteoarthritis" Chapter 12 In <u>Osteoarthritis: Diagnosis and Medical/Surgical Management</u> , Moskowitz, Howell, Goldberg and Mankin, Eds., WB Saunders Co., Harcourt Brace Jovanovich, pp. 313-328.
	31.	Balazs, E.A. and Denlinger, J. L. (1989). "Clinical Uses of Hyaluronan" In <u>Biology of Hyaluronan</u> . John Wiley & Sons, 143:265-275.
	32.	Batyrov, T.U. et al. (March-April 1982). "Experimental Study of the Local Anesthetic Action of Trimecaine Prolonged with Collagen," <i>Stomatologiya</i> 61(2): 7-10. (English Abstract).
	33.	Bentz, H. et al. (1998). "Improved Local Delivery of TGF- β 2 by Binding to Injectable Fibrillar Collagen Via Difunctional Polyethylene Glycol," <i>J. Biomed. Mater. Res.</i> 39:539-548.
	34.	Brahn, E. (April 1991). "Animal Models of Rheumatoid Arthritis: Clues to Etiology and Treatment," <i>Clin. Orthop. and Related Research</i> . 265:42-53.
	35.	Capaldi, M. J. and Chapman, J.A. (1982). "The C-Terminal Extrahelical Peptide of Type I Collagen and Its Role in Fibrillogenesis <i>In Vitro</i> ," <i>Biopolymers</i> 21:2291-2313.
	36.	Carron, H. (April 1978). "Relieving Pain with Nerve Blocks," <i>Geriatrics</i> 49-52,57.
	37.	Cepeda, M. S. et al. (1997). "Pain Relief After Knee Arthroscopy: Intra-Articular Morphine, Intra-Articular Bupivacaine, or Subcutaneous Morphine," <i>Reg. Anesth.</i> 22(3):223-238.
	38.	Cooperman, L. et al. (1984). "The Immunogenicity of Injectable Collagen I. a 1-Year Prospective Study," <i>J. of the Am. Acad. Dermatol.</i> 10:638-646.

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

RECEIVED

MAY 16 2002

PTO/SB/08 (2-92)

MAY 20 2002

TECH CENTER 1600/2900 Sheet 3 of 5

Form PTO-1449

Docket Number 437252001200

Application Number 10/082,443

INFORMATION DISCLOSURE

TECH CENTER 1600/2900

IN AN APPLICATION

Mark R. ALVIS et al.

Filing Date: February 22, 2002

Group Art Unit: 1614

Mailing Date: May 9, 2002



(Use several sheets if necessary)

- | | | |
|--|-----|--|
| | 40. | De Andres, J. et al. (1998). "Intra-Articular Analgesia After Arthroscopic Knee Surgery: Comparison of Three Different Regimens," <i>Eur. J. of Anaesth.</i> 15:10-15. |
| | 41. | Debruyne, D. et al. (1985). Monitoring Serum Bupivacaine Levels During Arthroscopy," <i>Eur. J. of Clin. Pharmacol.</i> 27:733-735. |
| | 42. | DeLustro, F. et al. (1987). "Reaction to Injectable Collagen: Results in Animal Models and Clinical Use," <i>Plast. Reconstruct. Surg.</i> 79:581-592. |
| | 43. | DeLustro, F. et al. (July 1988). "Immunity to Injectable Collagen and Autoimmune Disease: A Summary of Current Understanding," <i>Dermatol. Surg. Oncol.</i> 14(Suppl. 1)(7):57-65. |
| | 44. | Frank, D. H. et al. (June 1991). "Human Antibody Response Following Multiple Injections of Bovine Collagen," <i>Plast. Reconstruct. Surg</i> 87(6):1080-1088. |
| | 45. | Fraser, R. E et al. (June 1993). "The Kinetics of Hyalouronan in Normal and Acutely Inflamed Synovial Joints: Observation With Experimental Arthritis in Sheep," <i>Sem. Arthritis and Rheumatism</i> 22(6)(Suppl. 1):9-17. |
| | 46. | Frizziero, L et al. (1998). "Intra-Articular Hyaluronic Acid in the Treatment of Osteoarthritis of the Knee: Clinical and Morphological Study," <i>Clin. and Exp. Rheumatol.</i> 16:441-449. |
| | 47. | Gelman, R. A et al. (November 1979). "Collagen Fibril Formation <i>In Vitro</i> ," <i>J. Biol. Chem.</i> 254:11741-11745. |
| | 48. | Gradinger, R. et al. (June 1995). "Influence of Various Irrigation Fluids on Articular Cartilage," <i>Arthroscopy: The Journal of Arthroscopic and Related Surgery</i> 11(3):263-269. |
| | 49. | Henderson, R. C. et al. (1990). "Postarthroscopy Analgesia with Bupivacaine: A Prospective, Randomized, Blinded Evaluation," <i>The Am. J. of Sports Med.</i> 18(6):614-617. |
| | 50. | Horakava, P. Z. et al. (1967). "Prolongation Par Les Substances Collagènes De <i>Thérapie</i> 22(6): 1455-1460. (English Abstract) |
| | 51. | Kaeding, C. et al. (1990). "Bupivacaine Use After Knee Arthroscopy: A Pharmacokinetics and Pain Control Study," <i>Arthroscopy: The Journal of Arthroscopic and Related Surgery</i> 6(1):33-39. |
| | 52. | Konobevtsev, O. et al. (1982). "Local Anesthetic Effect of Trimecaine Prolonged by Collagen," <i>Stomatologiya</i> 61(5): 7-9. (English Abstract). |
| | 53. | Konobevtsev et al. (1986). "New Drug Forms of the Local Anesthetic Pyormecaine," <i>Anaesteziol Reanimatol</i> 0(3): 50-52. (English Abstract) |
| | 54. | Kroesen, S. et al. (2000). "Induction of an Acute Attack of Calcium Pyrophosphate Dihydrate Arthritis by Intra-Articular Injection of Hylan G-F 20 (Synvisc). <i>Clin. Rheumatol.</i> 19:147-149. |
| | 55. | Mah, E. T. et al. (1991). "Effects of Irrigation Fluid on Human Menisci: An Experimental Comparison of Water, Normal Saline and Glycine," <i>The Journal of Arthroscopie and Related Surgery</i> 7(1):24-32. |

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

MAY 16 2002

PTO/SB/08 (2-92)

Sheet 5 of 5

TECH CENTER 1600/2900

Form PTO-1449		Docket Number 437252001200	Application Number 10/082,443
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant	
		Mark R. ALVIS et al.	
		Filing Date: February 22, 2002	Group Art Unit: 1614
		Mailing Date: May 9, 2002	
		Solanki, D.R. et al. (1992). "Serum Bupivacaine Concentrations After Intraarticular Injection for Pain Relief After Knee Arthroscopy," <i>Arthroscopy</i> 8:44-47.	
	73.	Steffen, C. et al. (1975). "Collagen-Induced Acute Synovitis in Collagen-Immunized Rabbits," <i>A. Immun.-Forsch. Bd.</i> 150:432-446.	
	74.	Summary of Product Characteristics: Chirocaine® (Manufacturer: Abbott): 2 pages total.	
	75.	Wallace, D. G. et al. (1986). "Multiple Denaturational Transitions in Fibrillar Collagen," <i>Biopolymers</i> 25:1875-1893.	
	76.	Wasudev, G. et al. (1990). "Blood Levels of Bupivacaine After Arthroscopy of the Knee Joint," <i>Arthroscopy</i> 6(1):40-42	
	77.	Weiss, C. et al. (1986). "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions," <i>Bull. Hosp. Jt. Dis. Orthop. Inst.</i> 46:9-15.	
	78.	Weiss, C. et al. (1987). "The Role of Na-hylan in Reducing Postsurgical Tendon Adhesions: Part 2," <i>Bull. Hosp. Jt. Dis. Orthop. Inst.</i> 47:31-39.	
	79.	Whately, J. S. et al. (March 2000). "The Effect of an Exogenous Fibrin Clot on the Regeneration of the Triangular Fibrocartilage Complex: An In Vivo Experimental Study in Dogs," <i>Arthroscopy</i> 16:127-136.	
<p>RECEIVED MAY 20 2002 TECH CENTER 1600/2900</p>			
EXAMINER:		DATE CONSIDERED:	
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.			